MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS). The SEANOBI study, funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS initiative, has activated 12 sites in the United States and aims to enroll a total of 200 patients. The study is designed to provide access to MN-166 for ALS patients not eligible for ongoing randomized clinical trials and to collect clinical and biomarker data from a real-world population. In addition, MN-166 is being studied in the COMBAT-ALS Phase 2b/3 randomized, placebo-controlled trial with 234 patients enrolled in the U.S. and Canada. Top-line results from the COMBAT-ALS trial are expected by the end of 2026. No study results have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645407-en) on January 29, 2026, and is solely responsible for the information contained therein.